Today's Late-Breaking and Featured Science
Three Late-Breakers and three Featured Science presentations are on tap for today.
Late-Breaking Science
LBS.06 | Building on the Four Pillars: Novel Trials of Medical Therapy for Heart Failure
8:-9:15 a.m. | Main Event I
Heart Failure and Cardiomyopathies
- Myeloperoxidase Inhibition With Mitiperstat in Heart Failure With Preserved and Mildly Reduced Ejection Fraction: Primary Results From the ENDEAVOR Randomized Clinical Trial
- Effects of Sacubitril-Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial
- Novel Bumetanide Nasal Spray (BNS) Demonstrates Safety, Tolerability and Equivalent Efficacy Compared to Intravenous and Oral Bumetanide (RSQ-777-02)
- Sodium Zirconium Cyclosilicate and MRA Optimization in Heart Failure With Reduced Ejection Fraction and Hyperkalemia: Main Results From REALIZE-K Randomized Controlled Trial
LBS.07 | Revolutionizing AF Management: Cutting-Edge Approaches
9:45–11 a.m. | Main Event I
Electrophysiology and Arrhythmias
- Comparison of Linear Ablation Plus Pulmonary Vein Isolation vs. Pulmonary Vein Isolation Alone for Persistent Atrial Fibrillation: Results From the PROMPT-AF Randomized Trial
- Cryoballoon Ablation vs. Radiofrequency Ablation in Patients With Persistent Atrial Fibrillation (CRRF-PeAF): A Prospective, Multicenter, Randomized, Noninferiority Clinical Trial
- Randomized Controlled Trial of Metformin and Lifestyle/Risk Factor Modification for Upstream Prevention of Atrial Fibrillation Progression: The Targeting Risk Interventions and Metformin for Atrial Fibrillation (TRIM-AF) Trial
- Aggressive Risk Factor Reduction Study for Atrial Fibrillation (ARREST-AF) Implications for Ablation Outcomes: A Randomized Clinical Trial
LBS.08 | New Targets and New Treatments: Advances in Lipid Therapeutics
1:30–2:45 p.m. | Main Event I
Prevention and Lifestyle Medicine
- ALPACAR Phase 2 Trial of Zerlasiran: Multiple Doses of a Short-Interfering RNA Targeting Lipoprotein(a) Over 60 weeks.
- A Randomized Phase 2 Trial of Muvalaplin: An Oral Disrupter of the Assembly of Lipoprotein(a) Particles (KRAKEN)
- Safety and Efficacy of Obicetrapib in Patients With Heterozygous Familial Hypercholesterolemia (BROOKLYN)
Featured Science
FS.04 | Featured Science: Vascular Outcomes in the Spotlight
8–9:15 a.m. | S100A
Vascular Medicine
- Geographical Variations of Treatment Disparities Between Black and White Patients With Peripheral Artery Disease Across the United States
- Anatomically Directed Lower Extremity Gene Therapy for Ulcer Healing: A Double Blind, Randomized, Placebo Controlled Study (Legend 1 Trial)
- Bempedoic Acid and Limb Outcomes in Statin-Intolerant Patients With Peripheral Artery Disease: New Insights From the CLEAR OUTCOMES Trial
- Rivaroxaban for 18 Months vs. 6 Months in Cancer Patients With Low-Risk Pulmonary Embolism: ONCO PE Trial
FS.05: Featured Science | Amyloid, Hypertrophic and Danon Cardiomyopathies: Targeted Therapies and Specific Populations
9:45-11 a.m. | S103BC
- Danon Disease Phase 1 RP-A501 Results: The First Single-Dose Intravenous Gene Therapy With Recombinant Adeno-Associated Virus (AAV9:LAMP2B) for a Monogenic Cardiomyopathy
- Mavacamten Treatment in Patients With Obstructive HCM Referred for Septal Reduction Therapy: 128-Week Results From VALOR-HCM Trial
- Acoramidis Reduces All-Cause Mortality (ACM) and Cardiovascular-Related Hospitalization (CVH): Initial Outcomes From the ATTRibute-CM Open-Label Extension (OLE) Study
- Impact of Vutrisiran on Markers of Disease Progression in Patients With Transthyretin Amyloidosis With Cardiomyopathy in the HELIOS-B Trial
- The Prevalence of Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Individuals With Heart Failure: The Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations Study (SCAN-MP)
- ATTR-Specific Medication in Dual Pathology Aortic Stenosis and Transthyretin Cardiac Amyloidosis
FS.06 | Featured Science: Novel Insights in Cardiovascular Interventional Outcomes
1:30–2:45 p.m. | S100A
Surgery and Anesthesia
- Semaglutide Improves Cardiovascular Outcomes in Patients With a History of Coronary Artery Bypass Surgery and Overweight or Obesity: The SELECT Trial
- Five-Year Results From the AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial (Amulet IDE)
- The Impact of Carbon Monoxide to Determine the In-Hospital Prognosis After Acute Coronary Syndrome (ADDICT-ICCU)
- Quantitative Assessment of Mitral Annular Calcification Severity Predicts Outcomes in Severe Aortic Stenosis Patients Undergoing Transcatheter Aortic Valve Replacement
FS.07 | Featured Science: Incretin Modulation: Is a New Standard of Care Emerging?
1:30–2:45 p.m. | S103BC
Heart Failure and Cardiomyopathies
- Effect of Tirzepatide on Cardiac Structure and Function in Obese HFpEF: the SUMMIT CMR Substudy
- Effects of Tirzepatide on the Clinical and Symptom Burden of Patients With Heart Failure and a Preserved Ejection Fraction: Results From the SUMMIT Trial
- Benefits of Semaglutide on Chronic Kidney Disease Outcomes by Cardiovascular Status or Risk in the FLOW trial
For more information about these and other #AHA24 sessions, refer to the Online Program Planner.
